Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Most people reach 1 mg Wegovy after two dose increases
Zepbound Results (SURMOUNT-1 Trial) The SURMOUNT-1 trial studied 2,539 adults with obesity or overweight (without diabetes) over 72 weeks
A questionable COA will show only the final purity number with no supporting detail
Following that, corresponding secondary antibodies were used for blocking the sections for 30 min
Choose plain, unsweetened varieties to avoid excess sugar
continued treatment helps maintain losses Common side effects that may affect treatment adherence include: Nausea and vomiting (usually temporary, improving after several weeks) Diarrhoea or constipation Abdominal discomfort Fatigue Injection site reactions Important safety considerations include: Risk of hypoglycaemia if used with insulin or sulfonylureas [4] Do not stop or reduce insulin rapidly without medical advice (risk of diabetic ketoacidosis) [4] Maintain adequate hydration to prevent acute kidney injury [4] Potential for gallbladder problems (pain, stones) Rare risk of intestinal obstruction Possible worsening of diabetic retinopathy in people with diabetes during rapid improvement in blood glucose For tirzepatide: use additional non-oral contraception for 4 weeks after initiation and each dose escalation Patients should contact their GP if they experience: persistent vomiting preventing fluid intake, severe abdominal pain, signs of gallbladder disease, or unusual thyroid symptoms
